At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Differences in Cannabis Impairment and Its Measurement Due to Route of Administration
In Brief
A Phase 1 clinical trial evaluating cannabis for Behavioral Pharmacology of Cannabis. Completed, enrolled 23 participants across 1 site.
Detailed Summary
This research is being done to measure the effects of both oral and vaporized cannabis (marijuana), at different doses, on the ability to perform certain tasks such as balancing, eye tracking, and computerized measures of memory and attention, as well as performance on a novel app (DRUID) that is being developed for field sobriety testing. The investigators will collect biological fluids (urine, blood, saliva/spit) after cannabis is eaten or vaporized to see if there are markers in those fluids that can predict performance on the behavioral tasks and the DRUID App. The results of this study will help us better understand the effects of using cannabis, and to help identify behaviors and/or substances in the body that relate to cannabis impairment.
Study Details
Timeline
Interventions
Cannabis will be self-administered by study participants